Prednisone News and Research

RSS

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

IQWiG study finds considerable added benefit of abiraterone in prostate cancer patients

Abiraterone has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic drug docetaxel.

7 Jan 2012

$Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer$

Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer.

4 Jan 2012

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

Amgen today announced the U.S. Food and Drug Administration has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.

30 Dec 2011

Soligenix reports results from orBec Phase 2 trial on acute GVHD

Soligenix, Inc., a development stage biopharmaceutical company, announced the publication of results from its investigator-initiated Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

12 Dec 2011

BioInvent announces new BI-505 preclinical data on multiple myeloma

BioInvent International AB announced today that new preclinical data has been presented on its BI-505 programme that demonstrates anti-cancer activity in multiple myeloma and beneficial effect on bone density.

12 Dec 2011

New cancer research findings presented at 53rd ASH annual meeting

Researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine presented new research findings in 25 presentations this weekend at the 53rd Annual Meeting of the American Society of Hematology (ASH) at the San Diego Convention Center.

12 Dec 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

TNF inhibitors may minimally increase risk of serious infections

Biologic drugs have revolutionized treatment of autoimmune diseases during the past decade despite belief there is an increased risk for serious infections from using them. But new research from the University of Alabama at Birmingham Center for Education and Research on Therapeutics reveals that a class of biologics called tumor necrosis factor antagonists, or TNF inhibitors, may only minimally increase risk compared to more traditional therapies.

17 Nov 2011

Vitamin D supplementation benefits people with lupus

The first study to report the effects vitamin D has on the immune system of people with lupus was reported this week a the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Children with polyarticular JIA benefit from early and aggressive therapy

Children with juvenile arthritis who are treated early and aggressively have better outcomes, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Study finds pregnancy safe for 80% of women with lupus

Promising research led by investigators at Hospital for Special Surgery may offer hope for women with lupus who once thought that pregnancy was too risky.

7 Nov 2011

Allos third quarter net loss decreases to $11.2 million

Allos Therapeutics, Inc. today reported financial results for the three months ended September 30, 2011.

3 Nov 2011

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.

2 Nov 2011

NIH stops triple-drug therapy clinical trial for idiopathic pulmonary fibrosis

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has stopped one arm of a three arm multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic pulmonary fibrosis (IPF) for safety concerns.

22 Oct 2011

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%.

18 Oct 2011

Prostate cancer medicine deemed too-expensive by NHS

A drug used in therapy of prostate cancer that extends the lives of men with advanced prostate cancer is too expensive for use on the NHS, according to draft guidance. The drug has been shown to extend the lives of men with advanced prostate cancer by around 10 weeks.

2 Oct 2011

CSRO survey explores impact of health insurance barriers

The Coalition of State Rheumatology Organizations today released the findings of a nationwide survey that explored the impact of health insurance barriers such as prior authorization and step therapy on the ability of rheumatologists to provide effective care to patients.

1 Oct 2011

Combination of abiraterone acetate, prednisone reduces fatigue in men with prostate cancer

Men with prostate cancer that has spread to other parts of the body and that is resistant to hormone therapy suffer less from fatigue if they are treated with a combination of abiraterone acetate and prednisone, according to results from a phase III clinical trial presented today.

26 Sep 2011

Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer

Regeneron Pharmaceuticals, Inc. today announced that additional data from the Phase 3 VELOUR trial will be presented at the 2011 European Multidisciplinary Cancer Congress (EMCC) which will take place from September 23-27 in Stockholm, Sweden.

26 Sep 2011

Prednisone News and Research

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

IQWiG study finds considerable added benefit of abiraterone in prostate cancer patients

Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer

FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prostate cancer

Soligenix reports results from orBec Phase 2 trial on acute GVHD

BioInvent announces new BI-505 preclinical data on multiple myeloma

New cancer research findings presented at 53rd ASH annual meeting

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

TNF inhibitors may minimally increase risk of serious infections

Vitamin D supplementation benefits people with lupus

Children with polyarticular JIA benefit from early and aggressive therapy

Study finds pregnancy safe for 80% of women with lupus

Allos third quarter net loss decreases to $11.2 million

Takeda receives FDA approval for VELCADE sNDA to treat MM

NIH stops triple-drug therapy clinical trial for idiopathic pulmonary fibrosis

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Prostate cancer medicine deemed too-expensive by NHS

CSRO survey explores impact of health insurance barriers

Combination of abiraterone acetate, prednisone reduces fatigue in men with prostate cancer

Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer

Exploring the intersection of biology and proteomics

Unlocking the Secrets of Multiple Sclerosis Progression: Brain-Immune Cell Communication

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Latest News